SCARAB GENOMICS, LLC

Company Information
Address 1202 Ann St
MADISON, WI, 53713-2410

http://www.scarabgenomics.com

Information

DUNS: 105975036

# of Employees: 14


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains

    Amount: $154,222.00

    Scarab Genomics goal is to commercialize carrier proteins for conjugate vaccine manufacture This proposal focuses on two bacterial carrier proteins that have been approved by the FDA and that are in ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains

    Amount: $852,485.00

    Scarab Genomics goal is to commercialize carrier proteins for conjugate vaccine manufacture This proposal focuses on two bacterial carrier proteins that have been approved by the FDA and that are in ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  3. Characterization of a low mutation rate E. coli in extended fermentation

    Amount: $2,418,530.00

    DESCRIPTION provided by applicant Scarab Genomics was founded to improve E coli as an industrial organism by genome engineering These strains have stable genomes since all prophages transposable ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  4. Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain

    Amount: $1,461,610.00

    DESCRIPTION provided by applicant CRM is an inactive form of diphtheria toxin that when conjugated to a vaccine antigen enhances immunity to generate long lasting vaccination against the antig ...

    SBIRPhase II2014Department of Health and Human Services National Institutes of Health
  5. Characterization of a low mutation rate E. coli in extended fermentation

    Amount: $282,618.00

    DESCRIPTION (provided by applicant): This application aims to test a new Scarab E. coli strain, MDS42pdu, for commercial fermentation to produce biopharmaceuticals, amino acids and biofuels. It is des ...

    SBIRPhase I2013Department of Health and Human Services
  6. A protease-deficient, low mutation rate E. coli for biotherapeutics production

    Amount: $1,624,414.00

    DESCRIPTION (provided by applicant): Biotherapeutics is a fast-growth sector in the pharmaceutical market with monoclonal antibodies accounting for almost 50% of the 100 billion USD spent each year on ...

    SBIRPhase II2013Department of Health and Human Services
  7. Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain

    Amount: $140,925.00

    DESCRIPTION (provided by applicant): Scarab Genomics has developed valuable reduced-genome strains of Escherichia coli in which multiple deletions remove from the genome much unwanted and all potentia ...

    SBIRPhase I2012Department of Health and Human Services
  8. A protease-deficient, low mutation rate E. coli for biotherapeutics production

    Amount: $155,032.00

    DESCRIPTION (provided by applicant): Biotherapeutics is a fast-growth sector in the pharmaceutical market with monoclonal antibodies accounting for almost 50% of the 100 billion USD spent each year on ...

    SBIRPhase I2012Department of Health and Human Services
  9. Innate Immune Protection by Clean Genome E. coli

    Amount: $1,748,517.00

    DESCRIPTION (provided by applicant): Complications arising from pathogen infection incur a tremendous societal cost both in morbidity and mortality (as high as 50-60%), as well as in care and treatmen ...

    SBIRPhase II2011Department of Health and Human Services
  10. Uniform length DNA for paired end nextgen sequencing via in vitro packaging

    Amount: $127,387.00

    DESCRIPTION (provided by applicant): We have recognized an urgent need for a commercially applicable high throughput way to isolate pure DNA with long and uniform fragment length for nextgen genomic s ...

    SBIRPhase I2010Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government